Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Short-term Investments (2017 - 2024)

Rein Therapeutics (RNTX) has disclosed Short-term Investments for 8 consecutive years, with $25000.0 as the latest value for Q3 2024.

  • Quarterly Short-term Investments changed 0.0% to $25000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $25000.0 through Sep 2024, changed 0.0% year-over-year, with the annual reading at $25000.0 for FY2023, 0.0% changed from the prior year.
  • Short-term Investments for Q3 2024 was $25000.0 at Rein Therapeutics, roughly flat from $25000.0 in the prior quarter.
  • The five-year high for Short-term Investments was $44.6 million in Q3 2021, with the low at $25000.0 in Q1 2020.
  • Average Short-term Investments over 5 years is $8.4 million, with a median of $25000.0 recorded in 2020.
  • The sharpest move saw Short-term Investments skyrocketed 176172.0% in 2021, then tumbled 99.94% in 2022.
  • Over 5 years, Short-term Investments stood at $6.8 million in 2020, then crashed by 99.63% to $25000.0 in 2021, then changed by 0.0% to $25000.0 in 2022, then changed by 0.0% to $25000.0 in 2023, then changed by 0.0% to $25000.0 in 2024.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $25000.0, $25000.0, and $25000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.